What Is NeuroSense Therapeutics Ltd. (NRSN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on NeuroSense Therapeutics Ltd. at its current price of $0.72. The composite intrinsic value is estimated at $0.54 (-25.5% average return), with 4 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $1.21 (+69.0%), while ML-RIV — the most conservative — estimates $0.03 (-95.3%). This +164.3% gap reflects genuine analytical uncertainty about NeuroSense Therapeutics Ltd.'s intrinsic worth.
What Do the Models Say About NRSN?
7 of 13 models are currently active for NRSN. Of these, 3 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates NRSN's intrinsic value at $0.16, implying -77.5% downside from the current price. See which stocks rank higher →
How Does NRSN Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, NRSN ranks #281 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, NeuroSense Therapeutics Ltd. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating NRSN should weigh these sector-specific dynamics alongside our model-derived fair values.
Is NRSN a Value Trap?
The Value Trap algorithm is not active for NRSN. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for NeuroSense Therapeutics Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, NeuroSense Therapeutics Ltd.'s fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +164.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NRSN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NRSN's 7 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad